|
A recent article in the
Scandia Journal
reported that biotechnology is helping to
improve our knowledge of many devastating
illnesses, and has armed patients and their
doctors with exciting new diagnostics and
treatments to battle disease.
Biologic medicines, which
unlike traditional medicines are developed from
living matter, are exceedingly difficult to
develop and require substantial investment. The
Scandia Journal cites that biologics can take
"as much as $1.2 billion to research and
develop" and "take anywhere from 10 to 15 years
to get FDA approval."
|
|
Importantly, biologics offer
significant value to both patients and the health care
system. For example, they can delay the onset of
illness and reduce disease progression, which ultimately
can lead to overall cost-savings. Pharmaceutical
Research and Manufacturers of America (PhRMA) President
and CEO Billy Tauzin said: "Such critical innovation is
creating medicines with the potential to help millions
of patients live longer, healthier and more productive
lives."
America's pharmaceutical
research and biotechnology companies are leading the
charge. The article reported that 82 percent of global
biotech research and development was being driven by
U.S. biopharmaceutical companies. Tauzin added that,
"The biotechnology revolution is helping create
medicines that use unprecedented technologies, such as
nano-sized particles that seek out and target cancer
cells and ways to actually regenerate healthy muscle to
replace damaged heart tissue, and gene therapy."
DNA Electronics Wins R&D
Prize At Elektra09 European Electronics Industry Awards
|
|
 |
  |
Cardiovascular Clinical Trials in Emerging Countries |
|
10-11 May 2010 |
|
The globalisation of clinical trials has meant that
increasingly pharmaceutical and biotechnology
companies are turning towards performing clinical
trials in emerging markets such as Asia Pacific,
Central and Eastern Europe, Latin America and the
Middle East. However cultural, ethical, logistical
and regulatory challenges can prove to be the
biggest roadblocks when conducting trials in
emerging countries and this is particularly true
when conducting cardiovascular clinical trials. |
 |
|
All rights reserved